Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

ROTTERDAM, The Netherlands, September 7, 2011 /PRNewswire/ --

SIMPLE Antibody™ platform continues to demonstrate clear advantages in therapeutic antibody discovery


arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year's significant corporate progress  during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (http://www.ebdgroup.com/bpa/).

In his presentation on Friday, September 9, Mr. Van Hauwermeiren will showcase the speed with which arGEN-X has developed its pipeline of novel therapeutic antibody candidates in cancer and inflammatory disease. In less than two years of operations, the Company has identified three completely novel lead antibodies of unprecedented specificity and potency and progressed them into preclinical studies. arGEN-X is also combining the power of its SIMPLE Antibody™ platform with POTELLIGENT® Technology licensed from BioWa, Inc., to increase the cytotoxic potency of its therapeutic leads even further.

The arGEN-X presentation will also announce the successful fulfilment of all milestones in its first biopharma collaboration, only five months from its initiation in January 2011. Upon completion of this program, arGEN-X delivered a panel of unique, diverse antibodies against a technically complex target provided by the partner. This success demonstrated how the SIMPLE Antibody™ platform could generate antibodies with outstanding qualities, even against targets beyond the reach of other antibody platforms.

Speaking further about the exciting developments at arGEN-X, Mr. Van Hauwermeiren said:

"The signficant progress we have made in 2011 is proof that our unique SIMPLE Antibody™ Platform is tra
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Sciences, Inc. (NASDAQ: ALIM ) ("Alimera"), a ... commercialization of prescription ophthalmic pharmaceuticals, today announced that it ... financial results after the market close on Thursday, August ... the same day at 4:30 p.m. ET. ... Dan Myers , President and Chief Executive Officer, and ...
(Date:7/24/2014)... RALEIGH-DURHAM, N.C. , July 24, 2014 /PRNewswire/ ... company has signed an Agreement with Kineticos, a ... sciences consulting company. Kineticos will support LSI Medience ... in sepsis management, to demonstrate utility in clinical ... has shown potential utility in diagnosis of sepsis, ...
(Date:7/24/2014)... -- Perrigo Company (NYSE: PRGO ; TASE) today ... rating from the U.S. Food and Drug Administration (FDA) ... testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone product ... be substituted with the full expectation that it will ... AndroGel 1% when used under the conditions specified in ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... Memantine was initially developed by Merz to treat ... the brand name Akatinol; it was later licensed to Lundbeck ... the USA to Forest Labs as Namenda. Lundbeck reported the ... the US, Forest reported Namenda sales of USD 1.5 billion ... and the European region has increased the competition from generic ...
(Date:7/24/2014)... In signing the Workforce Innovation and ... Atlanta BeltLine Workforce Partnership in Healthcare as one ... ( http://www.whitehouse.gov/ready-to-work ). The Administration called for ... economic strategy and profiled successful local efforts to ... Obama highlights the power of partnerships in Atlanta,” ...
(Date:7/24/2014)... July 24, 2014 As the age ... to egg freezing as a way to ensure future ... otherwise decline with advancing reproductive age. Vitrification technology, a ... cutting edge medical technology that allows a woman to ... peak fertility years, which are then stored for future ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... radiation retinopathy who were destined to go blind within ... localized treatment with Avastin , a well-known cancer drug, ... 2007 Archives of Ophthalmology. ,This is a major ... radiation therapy and commonly develop radiation retinopathy, said Paul ...
... potentially lethal H5N1 strain of bird flu was confirmed this ... ,"All the turkeys on the farm have been killed and ... area, around 1,000 birds in all," Czech veterinary services spokesman ... (Friday)," he added. ,The H5N1 strain of bird flu ...
... people in Vietnam in the first six months of the ... period last year, the health ministry said Friday. ... 15 percent rise to 19,144 new infections from the mosquito-borne ... delta. ,Malaysia and other Southeast Asian countries have ...
... Researchers have formed a new compound AN2690, that might ... blocking an enzyme crucial for the protein synthesis of ... a team of researchers including Dickon Alley and Stephen ... Molecular Biology Laboratory (EMBL) outstation in Grenoble, France. ...
... an Anglo-American company has been allowed to store white ... by the US Food and Drug Administration. ... immune system that defend the body against both infectious ... take 480-millilitre of blood from interested healthy individuals and ...
... welcomed the European Union (EU) Parliament's resolution to ban mercury ... to do likewise. ,Toxics Link and other ... ,The group had called upon governments across the world to ... Programme (UNEP) in February. ,In one of ...
Cached Medicine News:Health News:Untreatable Eye Disease Improves With Avastin 2Health News:Researchers Devise New Compound to Treat Fungal Infections 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: